Kalaris Therapeutics, Inc. (NASDAQ: KLRS), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, has announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately US$50 million, before deducting placement agent fees and other offering expenses.
Latham & Watkins represents the placements agents in the transaction with a Capital Markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Jie Lin Nai and Elana Cates.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.